This Article  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Harry Most, M.D.
New York (16)

AMA Arch Intern Med. 1953;91(3):414.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

To the Editor::

—I wish to comment on the review of a book on bacitracin, published on page 424 in the September, 1952, issue of the ARCHIVES OF INTERNAL MEDICINE.

I have no personal interest in the publishers of the book, nor in bacitracin, with the exception that I did a good deal of work with this antibiotic. I do not believe that the reviewer's implication that bacitracin is made to be the drug of choice in the treatment of amebiasis by the book is justified on the basis of what is said in the book.

I believe that if the reviewer refers to the papers published on the therapy of amebiasis with bacitracin, he will find it stated that cure rates following use of this drug are approximately 65% and that the drug is apparently quite active in some instances in terminating episodes of acute ulcerative amebic colitis. Obviously, . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?